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ABSTRACT
There is an on-going debate about medicinal use of kratom plant (Mitragyna speciosa (MS)) on whether it has beneficial 
or adverse effects. This study aimed to examine long-term weight-reducing effects, toxicity, and dopamine pathway 
activation of MS alkaloid extract on adult male Wistar rats. In anorexic study, the rats were divided into 3 groups (n 
= 10), receiving intragastric administration once a day for 19 weeks as control (distilled water), chronic (20 mg/kg 
MS alkaloid extract) and withdrawal (20 mg/kg MS alkaloid extract for week 1-12 and distilled water for week 13-19) 
groups. Body weights were measured daily, and blood samples were collected at the end of study for biochemical and 
hematological tests. In immunohistochemistry, the effects of the extract (40 and 80 mg/kg) on the nucleus accumbens 
(NAc) and striatum (STr) were determined by using Fos-like immunoreactivity. From week 2 to 19, the results showed a 
significant reduction in body weight gain produced by the extract. Cessation of the treatment at week 12 did not result in a 
rebound weight gain. Chronic MS alkaloid extract treatment significantly decreased non-fasting blood sugar, triglyceride, 
uric acid and blood urea nitrogen (BUN). However, elevated SGOT may suggest possible hepatotoxicity. Chronic MS 
alkaloid extract treatment also produced baseline levels for most of the hematological parameters except a decrease of 
monocyte. In immunohistochemistry, the acute treatment did not induce Fos-like immunoreactivity in the NAc and STr. 
These data demonstrated the beneficial effects of the MS alkaloid extract for possible treatment of metabolic syndromes 
without toxicity and rewarding effect. 
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ABSTRAK
Terdapat perbahasan berterusan mengenai penggunaan tanaman kratom (Mitragyna speciosa (MS)) sebagai ubat, 
sama ada ia memberikan kesan yang baik atau buruk. Kajian ini bertujuan untuk mengkaji kesan pengurangan 
berat badan jangka panjang, ketoksikan dan pengaktifan jalur dopamin ekstrak alkaloid MS pada tikus Wistar jantan 
dewasa. Dalam kajian anoreksik, tikus dibahagikan kepada 3 kumpulan (n = 10), iaitu kumpulan kawalan yang 
menerima pemberian intragastrik sekali sehari selama 19 minggu sebagai kawalan (air suling), kumpulan kronik (20 
mg/kg MS alkaloid ekstrak) dan kumpulan penarikan (20 mg/kg ekstrak alkaloid MS untuk minggu 1-12 dan air suling 
untuk minggu 13-19). Berat badan diukur setiap hari dan sampel darah dikumpulkan pada akhir kajian untuk ujian 
biokimia dan hematologi. Dalam keimunan-histokimia, kesan ekstrak (40 dan 80 mg/kg) pada nukleus akumbens (NAc) 
dan striatum (STr) ditentukan dengan menggunakan reaktiviti imun mirip-Fos. Dari minggu 2 hingga 19, terdapat 
penurunan ketara dalam kenaikan berat badan yang dihasilkan oleh ekstrak tersebut. Penghentian rawatan pada 
minggu ke-12 tidak menyebabkan kenaikan berat badan. Rawatan ekstrak alkaloid MS kronik menurunkan gula darah 
tanpa puasa, trigliserida, asid urik dan nitrogen urea darah (BUN). Walau bagaimanapun, kenaikan SGOT mungkin 
menunjukkan kemungkinan kehepatotoksidan. Rawatan ekstrak alkaloid MS kronik juga menghasilkan tahap garis 
dasar bagi kebanyakan parameter hematologi kecuali penurunan monosit. Dalam keimunan-histokimia, rawatan akut 
tidak menyebabkan reaktiviti imun mirip-Fos pada NAc dan STr. Data ini menunjukkan kesan yang baik daripada 
ekstrak alkaloid MS untuk kemungkinan rawatan sindrom metabolik tanpa ketoksikan dan kesan ganjaran.
Kata kunci: Anorektik; ketagihan; ketoksikan; kratom; Mitragyna speciosa
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INTRODUCTION
The proportion of obese people is steadily increasing 
along with progressively increased health concerns such 
as diabetes, heart diseases, and hypertension (Ding & 
Mak 2015; Gallagher et al. 2010). Many classes of drugs 
are used for obesity treatment. Some selective serotonin 
reuptake inhibitors (SSRIs) that act as antidepressants were 
also found to reduce food intake and induce weight loss 
(Bitsch & Skrumsager 1987; McElroy et al. 2003). These 
drugs increase extracellular serotonin levels in the CNS. 
However, long-term use of some SSRIs caused weight 
gain (Sussman et al. 2001). In addition, the mental and 
physical side effects of some SSRIs have been consistently 
evidenced such as decreased sexual functioning (Ahrold 
& Meston 2009) or induced hallucinations and delusions 
(Capaldi & Carr 2010). 
Mitragyna speciosa (MS), called ‘kratom’ in 
Thailand, is a member of the Rubiacaea plant family. It 
has been used as a medicinal plant for centuries (Jansen 
& Prast 1988). Natural MS alkaloids appeared to contain 
several alkaloid components including mitragynine 
(0.33%), speciogynine (0.033%), paynantheine (0.043%) 
and other alkaloids (abundance less than 0.005%) (Ponglux 
et al. 1994). Mitragynine is a major indole alkaloid of 
MS shown to have an antinociceptive action. However, 
7-hydroxymitragynine, a minor constituent of this plant, 
also exhibited an even higher antinociceptive potency than 
that of mitragynine both in vitro (Takayama et al. 2002) 
and in vivo (Matsumoto et al. 2004). Moreover, other 
constituent alkaloids of the plant may also exert potent 
therapeutic effects.  
In terms of application as a medicinal product, MS 
has been widely investigated for its therapeutic and toxic 
effects. Apart from the antinociceptive action, anorectic 
and hypoglycemic activities are two main properties that 
have been intensively focused upon. Previously, alkaloid 
extract from MS was found to decrease food intake and 
reduce body weight in normal rats (Kumarnsit et al. 
2006). This finding suggested the efficacy of kratom as 
an alternative medicine for obesity treatment. Basically, 
withdrawal from habitual use of drugs such as tobacco, 
alcohol, cannabis, amphetamines, and cocaine, is 
followed by overeating which is an undesired outcome 
of rehabilitation (Edge & Gold 2012). In addition, the 
aqueous extract of this plant was demonstrated to attenuate 
ethanol withdrawal symptoms in animals (Kumarnsit et al. 
2006). However, further evaluation of long-term toxicity 
is needed in clinical levels. In particular, the addictive 
properties of kratom and other undesirable effects remained 
to be determined. 
Recently, many concerns were raised by research 
findings of pure mitragynine regarding its possible 
addictive property (Harun et al. 2015; Sufka et al. 2014; 
Yusoff et al. 2016). In conditioned place preference 
test, mitragynine effect was comparable to that of S(+)-
amphetamine in rats (Sufka et al. 2014). Moreover, acute 
and prolonged treatments (28 days) of mitragynine were 
demonstrated to have adverse effects on motor functions, 
learning and memory processes (Apryani et al. 2010). 
Particularly, the toxicity of mitragynine was confirmed by 
liver, kidney, and brain histopathological changes, as well 
as hematological and biochemical changes following 28 
days treatment (Sabetghadam et al. 2013). In contrast to 
pure mitragynine, the use of crude MS alkaloid extract 
has demonstrated many beneficial properties (Cheaha et 
al. 2015; Farah Idayu et al. 2011; Kumarnsit et al. 2007). 
Therefore, crude alkaloid extract of this plant was chosen 
for the investigation as a possible safer fraction for 
further applications. 
In general, addictive drugs such as amphetamine 
and cocaine are known to modulate dopamine release and 
uptake mechanism (Pifl et al. 1995; Sharp et al. 1987). This 
results in increasing extracellular dopamine in various 
brain areas. Particularly, this action of amphetamine 
was found in the NAc (nucleus accumbens) and STr 
(striatum) (Seiden et al. 1993). These two brain regions 
are terminal areas of the mesolimbic and nigrostriatal 
dopamine pathways, respectively. Repetitive activation 
of the NAc and STr by psychostimulants and opiates 
through dopaminergic action is believed to establish 
drug dependence (Hyman 1996). Activation of dopamine 
receptors in these areas increases cellular activity including 
gene expression via a variety of intracellular mechanisms. 
The expression of immediate early gene c-fos is of 
particular interest, especially as a result of activation by 
addictive drugs. Fos, a protein product of c-fos gene 
expression, can be induced by amphetamine (Graybiel 
et al. 1990). Therefore, Fos expression in the NAc and 
STr induced by psychostimulants and opiates has been 
consistently demonstrated (Ruksee et al. 2008).
In previous studies, crude alkaloid extract from MS 
significantly produced anorectic effects in rats following 
both acute and long-term treatments (Kumarnsit et al. 
2006). Therefore, the present study used the MS alkaloid 
extract to investigate its possible rebound effect on body 
weight, biochemical and hematological profiles, and 
stimulatory effect on the dopaminergic brain regions in 
a rat model. 
MATERIALS AND METHODS
PLANT MATERIALS AND EXTRACTION
Young leaves of MS were collected from natural 
sources in Songkhla and Satun provinces, Thailand 
during 2004-2005. Authentication of the plant material 
was carried out at the Department of Pharmacognosy 
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and Pharmaceutical Botany, Faculty of Pharmaceutical 
Sciences, Prince of Songkla University, Thailand where 
the herbarium voucher specimens (no. PCOG/MS001-002) 
have been deposited.
Extraction and isolation of the MS alkaloid extract 
were described in a previous study (Harizal et al. 2010). 
The major alkaloid, isolated by silica-gel column 
chromatography eluting with MeOH:CHCl3 (5:95), was 
identified as mitragynine with the standard spectroscopic 
methods (MS, 1H NMR, and 13C NMR). HPLC analysis for 
quantification of MS alkaloids including mitragynine, 
paynantheine, and speciogynine was performed as 
described previously (Harizal et al. 2010; Ponglux et al. 
1994). HPLC system equipped with HPLC SHIMADZU 
LC2030 3D was used. Column was VertiSepTM USP C18 
HPLC Column, 4.6 × 250 mm, 5 µm. The column was 
isocratically eluted with 20 mM ammonium acetate (pH 
6): acetonitrile; 35:65 (% v/v). The flow rate was 1 mL/
min. Injection volume was 20 µL and a UV detector was 
set at 225 nm. Amount of each alkaloid was expressed as 
mg/g of the alkaloid extract.
Prior to animal treatment, the solution of the MS 
alkaloid extract was prepared by dissolving the extract in 
co-solvent (tween 80: propylene glycol: H2O at a 1:4:4 
ratio) and adjusted to desired concentrations with distilled 
water.
ANIMALS
Male Wistar rats weighing 180-200 g at the start of 
the experiment were used. They were individually 
housed in wire-mesh cages (20×25×35 cm) with 
standard environmental conditions and fed with standard 
commercial food pellets and water ad libitum. Animals 
were acclimatized to this condition for at least one week 
prior to the experiment, provided they showed relatively 
stable food consumption. The protocols for care and use of 
experimental animals described in the present study were 
approved and guided by the Animals Ethical Committee 
of the Prince of Songkla University (MOE 0521.11/613).
MEASUREMENT OF ANIMAL’S BODY WEIGHTS
Rats were divided into 3 groups (N =10), a control group 
and 2 treatment groups (chronic and withdrawal groups). 
By using ball-tipped gavage needle attached to a syringe, 
they received intragastric administration of either 
distilled water or a dose of MS alkaloid extract (20 mg/
kg) at 6:00 p.m. daily for 19 consecutive weeks. The 
control group was fed with distilled water for the whole 
experiment. The chronic group was given MS alkaloid 
extract for 19 weeks while the withdrawal group received 
MS alkaloid extract for the first 12 weeks, followed with 7 
weeks of distilled water. During the experimental period, 
they could access food and water ad libitum. Body weights 
of animals were measured once a day throughout the 
experiment.
BLOOD BIOCHEMICAL AND HEMATOLOGICAL TESTS
On the final day, whole blood samples were collected 
through cardiac puncture. Each sample was transferred to 
a glass tube and mixed well with K3 EDTA and sodium 
fluoride as an anticoagulant and a glycolytic inhibitor, 
respectively. Therefore, blood biochemical parameters 
including non-fasting blood sugar, total cholesterol, 
triglyceride, uric acid, BUN, creatinine, total protein, 
albumin, total bilirubin, direct bilirubin, SGOT (serum 
glutamic oxaloacetic transaminase), SGPT (serum glutamic 
pyruvic transaminase), alkaline phosphatase, sodium and 
potassium were analyzed using Roche Cobas Mira S 
Chemistry Analyzer in the Central Laboratory (Hatyai, 
Songkhla, Thailand). Hematology was promptly conducted 
with an automatic analyzer. Morphology of blood cells 
was also thoroughly investigated by visual inspection 
for atypical lymphocyte, anisocytosis, hypochromia, 
microcyte, poikilocytosis, ovalocytosis and platelet on 
smear. Values of these parameters were immediately 
measured using Abbott Cell-Dyn CD-1800 Hematology 
Analyzer in the same laboratory to the blood biochemical 
test.
IMMUNOHISTOCHEMISTRY FOR FOS DETECTION IN THE 
BRAIN REGIONS OF DOPAMINE PATHWAYS
Animals were divided into a control group to receive saline 
and two treated groups to receive either 40 or 80 mg/kg 
of the MS alkaloid extract through intraperitoneal injection 
(i.p.). Morphine (5 mg/kg) was used as a positive control. 
All administrations were made between 9:00-9:15 a.m. 
To humanely terminate the animals, 2 h and 30 min after 
treatment, the rats were deeply anesthetized with sodium 
pentobarbitone (40 mg/kg). By itself, this anesthetic does 
not have a strong inducing effect on Fos expression in rat 
brains (Takayama et al. 1994). Animals were then perfused 
with fixative solution containing 4% paraformaldehyde in 
0.1 M phosphate buffer (PB) pH 7.4. Brains were removed 
and post-fixed overnight in the same fixative solution at 4 
°C. They were then transferred to sucrose solution (30% 
sucrose in 0.1 M PB) for cryoprotection until they sank. 
Brains were frozen and stored at -70 °C until the process 
for detection and localization of Fos protein. 
Coronal sections (40 µm) were cut through the 
forebrain with a cryostat between 2.20 mm and 0.70 
mm anterior to the bregma. The rat brain atlas was 
used for confirmation of the NAc and STr brain areas. 
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The free-floating sections were incubated with anti-Fos 
antibodies raised in sheep (Chemicon, CA, USA) diluted 
1: 100 in PBT (PB containing 5% normal donkey serum 
and 0.3% TritonX100 overnight at 4 °C and washed 
3× 15 min with PB. They were then incubated with 
fluorescein isothiocyanate (FITC)-conjugated anti-sheep 
immunoglobulin antibodies (Chemicon, CA, USA) for 2 
h at room temperature and washed 3 times 15 min with 
PB. Sections were mounted on glass slides. Images were 
captured with an Olympus DP-50 digital camera and 
image files were processed using Microimage software 
(Olympus). 
 Controls for non-specific staining were performed 
in which primary antibody was omitted. The images 
were viewed with a PC computer using the Adobe 
Photoshop 7.0 program. Sections were coded with 
random numbers to prevent bias in quantification. Fos-
like immunoreactive nuclei were counted in the NAc 
and STr. At least 10 separate brain sections from each 
rat were used for quantification. The numbers of Fos-
like immunoreactive cells per section were counted 
bilaterally and averaged for each rat.
STATISTICAL ANALYSIS
Body weights of animals were measured once a day and 
the values of the final day in each week were chosen to 
represent as the body weight of that week. All values 
of body weight, hematological, blood biochemical 
parameters and numbers of Fos-like immunoreactive 
cells of each group were presented as mean ± SEM. 
Statistical differences between the control and the MS 
alkaloid extract-treated groups were determined by using 
one-way analysis of variance followed by Tukey method 
for body weight and Fos detection and Student’s t-test for 
hematological and blood biochemical tests. Significant 
level with P˂0.05 was used for all statistical analyses.
RESULTS
CHARACTERISTIC OF MS ALKALOID EXTRACT
The MS alkaloid extract appeared as a dark brown 
mass. Determination of the alkaloids in the extract by 
HPLC showed the presence of mitragynine 47.1 mg/g, 
paynantheine 8.4 mg/g and speciogynine 2.2 mg/g, 
which accounted for 82, 14, and 4% of the total alkaloids 





FIGURE 1. HPLC chromatogram of the MS alkaloid extract. 1: speciogynine 
at 9.3 min; 2: paynantheine at 10.3 min; 3: mitragynine at 13.9 min
EFFECT OF CHRONIC ADMINISTRATION AND 
WITHDRAWAL OF MS ALKALOID EXTRACT ON BODY 
WEIGHT
During the experiment, none of the rats perished, nor was 
there obvious change of behavior recorded in any group 
except the decreases of feeding behavior. The effect of 
chronic administration of the MS alkaloid extract on body 
weight was analyzed (Figure 2). One-way ANOVA showed 
significant effects of either chronic or withdrawal of MS 
alkaloid extract treatment (p < 0.001). Treated animals 
exhibited significantly lower body weights than control 
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levels. Significant differences between control and MS 
alkaloid extract treated groups were detected from the 
2nd to the final week. The difference was progressively 
obvious by time. After a 19-week treatment, both chronic 
and withdrawal groups equally reduced body weight gain 
in comparison to control group. Their body weights were 
about 360 g compared to 400 g of control animals. In 
the withdrawal group after the MS alkaloid extract was 
withdrawn, no rebound weight gain was found during 
the MS alkaloid extract-free period. Their body weights 
did not return to control levels. In fact, the MS alkaloid 
extract withdrawal animals had about the same weight as 
the chronic animals.
FIGURE 2. Effects of chronic treatment and withdrawal of MS alkaloid extract on body weight of rats. 
Mean body weights measured on final day of each week in each group were selected to represent data 
points. Data are expressed as mean ± SEM (n = 10). *, *** P< 0.05, 0.001 respectively, significantly 
different from control levels. The straight horizontal line represents a continuous period of significant 
differences between groups with P< 0.001
EFFECTS OF CHRONIC ADMINISTRATION OF MS 
ALKALOID EXTRACT ON BLOOD CHEMICAL 
PARAMETERS
Blood biochemical parameters of control and chronic MS 
alkaloid extract groups were expressed (Table 1). The 
mean level of non-fasting blood sugar was significantly 
decreased after 19-week MS alkaloid extract treatment 
(p˂0.05). Chronic group had 117.89±23.01 mg% whereas 
control group had 176.89±15.42 mg%. From lipid analysis, 
the treatment significantly reduced triglyceride (p˂0.05) 
but had no effect on total cholesterol level. Triglyceride 
level following chronic treatment with the MS alkaloid 
extract (45.89±11.01 mg%) was significantly lower 
than control level (80.11±12.29 mg%). Additionally, 
the concentration of uric acid was significantly reduced 
(p˂0.05) from 1.99±0.68 mg% of control level to 
1.14±0.12 mg% following the chronic treatment. 
Parameters of renal functions indicated a significant 
reduction of BUN (p˂0.01) but not creatinine. BUN level 
was decreased from 23.00±1.25 mg% (control level) to 
17.78±0.72 mg/dL following the chronic treatment. Liver 
function parameters were found to remain unchanged 
mostly except only the increase of SGOT (p˂0.01). SGOT 
was significantly increased from 138.78±7.35 U/L to 
190.44±19.71 U/L following the chronic treatment.
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TABLE 1. Effects of chronic treatment with MS alkaloid extract (19 weeks) on blood biochemical parameters in rats
Parameters Control Chronic MS
Non-fasting blood sugar (mg%) 176.89 ± 15.42 117.89 ± 23.02*
Total cholesterol (mg%) 58.56 ± 2.42 56.33 ± 2.74
Triglyceride (mg%) 80.11 ± 12.29 45.89 ± 11.01*
Uric acid (mg%) 1.99 ± 0.68 1.21 ± 0.30*
BUN (mg%) 23.00 ± 1.25 17.78 ± 0.72**
Creatinine (mg%) 0.66 ± 0.04 0.57 ± 0.04
Total protein (g%) 6.71 ± 0.18 6.59 ± 0.12
Albumin (g%) 2.24 ± 0.06 2.41 ± 0.12
Total bilirubin (g%) 0.13 ± 0.02 0.10 ± 0.00
Direct bilirubin (g%) 0.03 ± 0.02 0.01 ± 0.01
SGOT [AST] (U/L) 138.78 ± 7.35 190.44 ± 19.71*
SGPT [ALT] (U/L) 73.00 ± 3.34 73.89 ± 12.97
Alkaline phosphatase (U/L) 151.44 ± 16.23 130.44 ± 7.07
Sodium (mmole/L) 141.44 ± 2.13 140.22 ± 2.03
Potassium (mmole/L) 6.89 ± 0.27 7.63 ± 1.08
                Data are expressed as mean ± SEM (n = 10). *, ** P< 0.05, 0.01 respectively, significantly different from control levels
EFFECTS OF CHRONIC ADMINISTRATION OF 
MS ALKALOID EXTRACT ON HEMATOLOGICAL 
PARAMETERS
After a 19-week treatment MS alkaloid extract, a 
significant difference was observed only in % monocyte 
(p˂0.01) which was decreased from about 6.44±1.70 
to 2.13±0.84% (Table 2). Values of hemoglobin, 
hematocrit, white blood count, % differential neutrophil, 
% lymphocyte, and platelet count remained unchanged. 
The investigation of blood cell morphology showed 
the levels (control/chronic MS alkaloid treatment) of 
hemoglobin (12.97 ± 1.10/13.44 ± 1.58), % hematocrit 
(36.79 ± 3.51/30.73 ± 4.29), white blood count (3444.44 ± 
406.24/4955.56 ± 922.65), % differential neutrophil (33.11 
± 3.87/41.11 ± 4.72), % lymphocyte (58.78 ± 4.03/55.89 
± 4.79 and platelet count (362111 ± 216544/119556 
± 16656). The atypical lymphocyte, anisocytosis, 
hypochromia, microcyte, poikilocytosis, ovalocytosis of 
blood cells were rarely found both in chronic and control 
groups. No significant difference of these parameters was 
seen between treated and control groups.
TABLE 2. Effects of chronic treatment with MS alkaloid extract (19 weeks) on hematological parameters in rats
Parameters Control Chronic MS
Hemoglobin (mg%) 12.97 ± 1.10 13.44 ± 1.58
Hematocrit (%) 36.79 ± 3.51 30.73 ± 4.29
White blood count (µL) 3444.44 ± 406.24 4955.56 ± 922.65
% Differential neutrophil 33.11 ± 3.87 41.11 ± 4.72
% Lymphocyte 58.78 ± 4.03 55.89 ± 4.79
% Monocyte 6.44 ± 1.70 2.13 ± 0.84*
Platelet count (µL) 362111 ± 216544 119556 ± 16656
Data are expressed as mean ± SEM (n = 10). * P< 0.05, significantly different from control levels
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EFFECTS OF MS ALKALOID EXTRACT ON FOS-LIKE 
IMMUNOREACTIVITY IN THE NUCLEUS ACCUMBENS 
AND STRIATUM
Rat brain slices of control and treated groups showed 
Fos-like immunoreactivity in some brain areas. The 
immunoreactivity was present in selected cell nuclei. 
The fluorescein isothiocyanate (FITC) staining signals 
were similar to those observed in our previous study 
(Kumarnsit et al. 1999). The region of NAc was identified 
as the area surrounding the anterior commissure (anterior 
part, aca) while the STr as the area below corpus callosum. 
Representative brain sections containing Fos-positive 
signals in the NAc and STr are shown in Figure 3(A) and 
3(B), respectively. High magnified images of positive 
signals from saline control and morphine treated animals 
are also shown in Figure 3(C) and 3(D). Obviously, higher 
density of positive signals induced by morphine was 
clearly seen compared to that of saline control.
FIGURE 3. Representative brain sections showing Fos-like immunoreactivity in 
nucleus accumbens (A-C) and striatum (D-F) of rats treat with saline and the MS 
alkaloid extract (40 and 80 mg/kg). All data are mean ± SEM (n=7 in each group)
The brain sections of control animals that received 
saline showed baseline levels of Fos-like immunoreactivity. 
The immunoreactive cells appeared to be scattered evenly 
in the NAc (Figure 4(A)-4(C)). Sections from the rat that 
received 40 or 80 mg/kg MS alkaloid extract showed 
similar patterns of immunoreactivity to that of control 
group. Numbers of positive signals were counted and 
analyzed as density per 10000 µm2 (Figure 4(G)). The 
control group exhibited an average value of 16.6 Fos-like 
immunoreactive cells per 10000 µm2 whereas the groups 
treated with 40 or 80 mg/kg MS alkaloid extract had the 
value of 20 and 18.8 per 10000 µm2, respectively. The 
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differences of density number among these groups were 
not statistically significant.
In the STr, the evenly distribution patterns of Fos-like 
immunoreactivity in each brain slice were also observed 
(Figure 4(D)-4(F)). The control group exhibited an average 
value of 16.5 Fos-like immunoreactive cells per 10000 
µm2 whereas the groups treated with 40 and 80 mg/kg 
MS alkaloid extract had the values of 16.8 and 14.8 per 
10000 µm2, respectively (Figure 4(H)). The differences of 
density number between these groups were not statistically 
significant.
FIGURE 4. Detection of Fos-like immunoreactivity in nucleus accumbens (A) and striatum (B) 
of rat brain. Brain sections were incubated with anti-Fos antibodies and visualized with FITC 
labeled secondary antibodies using confocal microscope. Anterior commissure (aca) is a landmark 
of nucleus accumbens while corpus callosum is of stiatum. White arrows indicate dense nuclear 
staining in these brain areas. Representative brain section showing Fos-like immunoreactivity in 
nucleus accumbens of rats treated with saline (C) and morphine (D)
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DISCUSSION
The present study demonstrated a chronic weight-reducing 
effect in rats without tolerability and rebound effect. No 
blood test parameter reflected obvious toxicity following 
a 19-week administration of MS alkaloid extract. Basically, 
hematological parameters were used to report toxicity 
induced by toxin (Zhao et al. 2019) or pharmacological 
substances (Chakroun et al. 2016; Ito et al. 2018). The 
present results also demonstrated that the MS alkaloid 
extract did not induce Fos-like immunoreactivity in the 
NAc and STr. These findings suggest beneficial and non-
toxic effects of kratom when whole alkaloid extract was 
used acutely or in a short period of treatment.
Anorectic effect of the MS alkaloid extract might 
be produced by multiple alkaloid constituents exhibiting 
multiple actions in the CNS. Apart from the major alkaloid 
mitragynine, various alkaloids in the MS plant have 
been isolated and identified (Limsuwanchote et al. 2017; 
Ponglux et al. 1994). Though its actions on opioid receptors 
were most consistently detected but other pathways 
such as serotonergic or noradrenergic pathways were 
also activated by the MS extracts such as crude alkaloid 
(Kumarnsit et al. 2007) or pure mitragynine (Matsumoto 
et al. 1996). In addition to its opioid receptor-mediated 
antinociception, anorectic (Kumarnsit et al. 2006) and 
antidepressant (Kumarnsit et al. 2007) effects were also 
induced by the MS alkaloid extract. Anyway, activations of 
either opioidergic (Nathan & Bullmore 2009), serotonergic 
(Apryani et al. 2010) or noradrenergic (Ahlskog & Hoebel 
1973; Apryani et al. 2010) pathways were associated with 
a loss of appetite as a common action. Mitragynine had 
relatively lower potency when compared to morphine in 
terms of antinociception (Horie et al. 2005) and probably 
also for anorexigenic action (Leshem 1981; Wiffen et 
al. 2014). This might explain why tolerance effects was 
not observed during the negative energy balance period 
induced by a 19-week MS alkaloid extract treatment. 
In general, potent anorectic drugs that activate specific 
CNS pathway such as sibutramine (Gursoy et al. 2006), 
fluoxetine or fenfluramine (McGuirk et al. 1992) regularly 
have tolerance and result in hyperphagia and weight regain 
in compensation. 
The mechanism of the MS alkaloid extract on blood 
sugar levels has not been consistently investigated. At 
least, the enhancement of glucose uptake was confirmed 
as one of the mechanisms that may reduce blood sugar 
(Purintrapiban et al. 2011). However, no longer treatment 
has been performed. The present data demonstrated 
the decreased uric acid and BUN following chronic MS 
alkaloid extract treatment. These findings might reflect a 
low breakdown of protein. Normally, they are removed 
from the blood by the kidney and excreted out of the body 
in urine or feces. The increase of uric acid is associated 
with gout whereas its decrease is rare and not related 
to serious diseases. In general, liver disease or damage 
can be detected with increased BUN and creatinine. 
The decrease of BUN and unchanged level of creatinine 
suggested that chronic MS alkaloid extract treatment did 
not induce kidney malfunction. The decreases in levels 
of uric acid and BUN in this study may be collectively 
interpreted as consequences of low food consumption 
during a period of MS alkaloid extract treatment. The 
integrity of hepatocyte was also evaluated from levels of 
various proteins and enzymes tested. SGOT, also known 
as aspartate aminotransferase, was elevated by chronic MS 
alkaloid extract treatment. In some pathologies such as 
alcoholism (Himmelstein et al. 1984) or abdominal trauma 
(Karaduman et al. 2003), the elevated SGOT indicates 
possible hepatotoxicity. However, the hepatic dysfunction 
was unlikely to be induced by this treatment as the rest 
of liver function parameters remained unchanged. The 
stable levels of sodium and potassium ion concentrations 
also confirmed that the internal environment of the body 
remained well-regulated.
The chronic MS alkaloid extract treatment seemed to 
have minimal effects on components and morphology of 
blood cells. The decrease of % monocytes was the only 
one significant change among other parameters. Previously, 
monocytes/macrophages were decreased in a murine model 
of methamphetamine consumption that might suggest 
immunosuppression (Harms et al. 2012). Percent (%) of 
monocytes is normally increased in case of inflammation 
(Janardhan et al. 2006). Altogether, the decrease of % 
monocytes and unchanged levels of white blood count, % 
differential neutrophil and % leucocyte may suggest no 
infection and guarantee a normal range of components, 
hemopoiesis and function of the blood cells during chronic 
MS alkaloid extract treatment.
The two doses used in this study were effective 
especially in anorectic actions (Kumarnsit et al. 2006). 
Increasing the dose in attempt to elevate the level of Fos 
expression might result in overdose toxicity. Sensitivity 
of the immunohistochemistry method is also critical 
for detection and comparison of Fos expression levels. 
In this study, Fos-like immunoreactivities of baseline 
and morphine-induced levels in the NAc were clearly 
distinguishable. Previously, this method was used to 
demonstrate that pseudoephedrine, a diastereoisomer of 
ephedrine, induced Fos-like immunoreactivity in the NAc 
and STr (Kumarnsit et al. 1999). This indicates that the 
technique used was sensitive and suitable for this study. 
The present data suggest that the MS alkaloid extract 
had no stimulatory effect on the NAc and STr. The former 
brain area is recognized as the rewarding brain center and 
the latter one recognized as one of dominant regions of 
dopaminergic pathways involved in motor function. This 
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result was consistent with the findings of our previous 
study using the local field potential recording directly 
from the nucleus accumbens which indicated that the 
MS alkaloid extract (80 mg/kg) does not affect the neural 
signaling of the nucleus accumbens (Cheaha et al. 2017). 
Most of psychostimulants and opiates activate these 
brain areas. It means that the MS extract does not possess 
rewarding property. This may be the reason why this plant 
is usually used in combination with some other stimulant 
substances as cocktails in order to gain desirable levels of 
psychoactive effects. The use of kratom plant as a single 
substance does not seem to have such effect. Anyway, 
rewarding or addictive properties can be examined by 
using a variety of methods. Among those methods, self-
administration is the most straight forward and reliable 
technique to determine whether the substance tested has 
addictive effects (Doherty & Frantz 2012; Liu et al. 2007). 
To examine addictive action of the MS alkaloid extract 
precisely, the self-administration technique is needed for 
confirmation. Further studies with longer administration 
periods are needed.
CONCLUSION
In summary, the treatment with MS alkaloid extract 
at 20 mg/kg for 19 weeks produced a decrease in body 
weight gain. An abrupt cessation after a 12-week period 
of MS alkaloid extract treatment was not followed by a 
rebound weight gain. There was also no indicator from 
biochemical and hematological tests that emphasized 
serious toxic effects of the MS alkaloid extract. Moreover, 
the MS alkaloid extract did not induce Fos expression in 
the brain rewarding center. This study suggests that MS 
may have beneficial effects for obesity treatment without 
activation on the dopaminergic brain region as observed 
following treatment with general psychostimulants and 
addictive substances.
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